Kymera Therapeutics, Inc. (KYMR)
KYMRNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$138.86
+7.00 (+5.31%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $11.85bn
- P/E
- –
- EPS, last 4 quarters
- $-3.62
- Dividend yield
- –
- Day range
- –
- 52-week range
- $56.75 to $138.00
- Average volume
- 849.2k
- Previous close
- $131.86
Analysts
15 coveringBuy13 buy, 2 hold, 0 sell
Targets a year out average $147.67, +6.3% from here
Earnings
next estimate $-1.29Next report
Dec 2025
-26.0%
Mar 2026
+20.2%
Jun 2026
+3.1%
Sep 2026
-4.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $2.87m | $34.37m | $65.00m | – |
| Gross profit | $2.87m | $34.37m | $65.00m | – |
| Operating income | -$97.90m | -$84.15m | -$75.61m | -$147.23m |
| Net income | -$86.98m | -$69.23m | -$61.21m | -$132.00m |
News
8 latest- Kymera (KYMR) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- Kymera Therapeutics Q3 Earnings Call HighlightsMarketBeat · Oct 29, 2026
- Kymera Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Positive KT-579 Phase 1 Trial DataFintel · Oct 29, 2026
- Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowZacks · Oct 26, 2026
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Zacks · Oct 19, 2026
- Raymond James Initiates Coverage of Kymera Therapeutics with Outperform RatingFintel · Oct 9, 2026
- Stocks Retreat as 10-year T-note Yield Reaches New 2.75-year HighBarchart · Sep 10, 2026
- Stocks Slump as Crude Prices Soar and Bond Yields SurgeBarchart · Sep 10, 2026
The company
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- kymeratx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.